Can Engineered “Designer” T Cells Outsmart Chronic Hepatitis B?

More than 350 million people worldwide are persistently infected with human heptatitis B virus (HBV) and at risk to develop liver cirrhosis and hepatocellular carcinoma making long-term treatment necessary. While a vaccine is available and new antiviral drugs are being developed, elimination of pers...

Descripción completa

Detalles Bibliográficos
Autores principales: Protzer, U., Abken, H.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004001/
https://www.ncbi.nlm.nih.gov/pubmed/21188203
http://dx.doi.org/10.1155/2010/901216
_version_ 1782193939725418496
author Protzer, U.
Abken, H.
author_facet Protzer, U.
Abken, H.
author_sort Protzer, U.
collection PubMed
description More than 350 million people worldwide are persistently infected with human heptatitis B virus (HBV) and at risk to develop liver cirrhosis and hepatocellular carcinoma making long-term treatment necessary. While a vaccine is available and new antiviral drugs are being developed, elimination of persistently infected cells is still a major issue. Recent efforts in adoptive cell therapy are experimentally exploring immunotherapeutic elimination of HBV-infected cells by means of a biological attack with genetically engineered “designer” T cells.
format Text
id pubmed-3004001
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-30040012010-12-23 Can Engineered “Designer” T Cells Outsmart Chronic Hepatitis B? Protzer, U. Abken, H. Hepat Res Treat Review Article More than 350 million people worldwide are persistently infected with human heptatitis B virus (HBV) and at risk to develop liver cirrhosis and hepatocellular carcinoma making long-term treatment necessary. While a vaccine is available and new antiviral drugs are being developed, elimination of persistently infected cells is still a major issue. Recent efforts in adoptive cell therapy are experimentally exploring immunotherapeutic elimination of HBV-infected cells by means of a biological attack with genetically engineered “designer” T cells. Hindawi Publishing Corporation 2010 2010-09-21 /pmc/articles/PMC3004001/ /pubmed/21188203 http://dx.doi.org/10.1155/2010/901216 Text en Copyright © 2010 U. Protzer and H. Abken. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Protzer, U.
Abken, H.
Can Engineered “Designer” T Cells Outsmart Chronic Hepatitis B?
title Can Engineered “Designer” T Cells Outsmart Chronic Hepatitis B?
title_full Can Engineered “Designer” T Cells Outsmart Chronic Hepatitis B?
title_fullStr Can Engineered “Designer” T Cells Outsmart Chronic Hepatitis B?
title_full_unstemmed Can Engineered “Designer” T Cells Outsmart Chronic Hepatitis B?
title_short Can Engineered “Designer” T Cells Outsmart Chronic Hepatitis B?
title_sort can engineered “designer” t cells outsmart chronic hepatitis b?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004001/
https://www.ncbi.nlm.nih.gov/pubmed/21188203
http://dx.doi.org/10.1155/2010/901216
work_keys_str_mv AT protzeru canengineereddesignertcellsoutsmartchronichepatitisb
AT abkenh canengineereddesignertcellsoutsmartchronichepatitisb

Ejemplares similares